Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.

Related Articles Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. Dig Dis Sci. 2019 Jan 02;: Authors: Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P Abstract BACKGROUND: The benefits of immunosuppressants for sustaining remission and preventing flares of IBD are well known. However, optimal timing for withdrawal has not been determined. AIMS: The objective of this study was to calculate the risk of relapse and predictors after withdrawal of azathioprine…

Read More

Usefulness of Thiopurine Monotherapy for Crohn’s Disease in the Era of Biologics: A Long-Term Single-Center Experience.

Related Articles Usefulness of Thiopurine Monotherapy for Crohn’s Disease in the Era of Biologics: A Long-Term Single-Center Experience. Dig Dis Sci. 2018 Dec 12;: Authors: Suárez Ferrer C, González-Lama Y, González-Partida I, Calvo Moya M, Vera Mendoza I, Matallana Royo V, Arevalo Serrano J, Abreu Garcia L Abstract BACKGROUND: Thiopurines are classically used in Crohn’s disease (CD). Treatment fails in a proportion of patients either due to adverse events (AE) or lack of efficacy. Increasing use of anti-TNFα biologic drugs may have had impact on thiopurines usage. AIM: To evaluate…

Read More

Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn’s Disease.

Related Articles Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn’s Disease. Dig Dis Sci. 2018 Dec 17;: Authors: Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow MP, Gibson PR, van Langenberg DR Abstract BACKGROUND: The differential impact of anti-tumor necrosis factor (anti-TNF) therapy with methotrexate versus thiopurine co-therapy on endoscopic remission remains uncertain. AIMS: To compare rates of endoscopic remission based on methotrexate or thiopurine co-therapy used with anti-TNF therapy in Crohn’s disease. METHODS: A retrospective observational study at two…

Read More

Risk of Skin Cancers in Thiopurines-treated and Untreated patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Related Articles Risk of Skin Cancers in Thiopurines-treated and Untreated patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Gastroenterol Hepatol. 2018 Nov 04;: Authors: Huang SZ, Liu ZC, Liao WX, Wei JX, Huang XW, Yang C, Xia YH, Li L, Ye C, Dai SX Abstract BACKGROUND AND AIM: The thiopurines are effective in the management of patients with inflammatory bowel disease (IBD), but the association between thiopurines use and the risk of skin cancer (including nonmelanoma skin cancer [NMSC] and melanoma skin cancer [MSC]) has already been…

Read More

Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis.

Related Articles Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis. Gut. 2018 Oct 09;: Authors: Hammoudi N, Gardair C, Tran-Minh ML, Allez M, Gornet JM Abstract QUESTION: A 58-year-old, non-smoker male patient with no family history was followed up since 2002 for ulcerative colitis (UC) located in the rectosigmoid. He was initially treated by salicylates alone until November 2008. Mercaptopurine was started in August 2009 for steroid dependence with primary failure despite adequate 6 thioguanine nucleotides (6 TGN) level. He…

Read More

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy-a Post-hoc analysis.

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy-a Post-hoc analysis. Clin Gastroenterol Hepatol. 2018 Sep 26;: Authors: Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D’Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB Abstract BACKGROUND & AIMS: Among immunosuppressive- and biologic-naïve patients with moderate to severely active Crohn’s disease (CD), a higher proportion of those treated with the combination of infliximab and azathioprine achieved corticosteroid-free remission at week 26 (CSFR26) than those given infliximab monotherapy; patients given the combination therapy also had…

Read More

The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios.

The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios. Inflamm Bowel Dis. 2018 Sep 27;: Authors: Selinger CP, Ochieng AO, George V, Leong RW Abstract Background: Adherence to maintenance medication for inflammatory bowel disease (IBD) is essential for disease control, albeit often poor. Adherence can be measured by drug metabolites, self-report tools, and prescription data. The aim of this study was to test implementation of self-report tools in IBD clinics by evaluating consistency and to…

Read More

Pharmacokinetics and immune reconstitution following discontinuation of thiopurine analogues: Implications for drug withdrawal strategies.

Pharmacokinetics and immune reconstitution following discontinuation of thiopurine analogues: Implications for drug withdrawal strategies. J Crohns Colitis. 2018 Aug 27;: Authors: Ben-Horin S, Van Assche G, Chowers Y, Fudim E, Ungar B, Picard O, Yavzori M, Kopylov U, Ren M, Chen MH, Peled-Potashnik Y, Gueta I, Eliakim R, Loebstein R, Markovits N Abstract Introduction: Thiopurine analogues discontinuation is common prior to live vaccines, during infection or when de-escalating therapy. Data regarding clearance of active metabolites and immune re-constitution is scant. Objectives: To determine drug elimination and immune re-constitution following thiopurine…

Read More

Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis.

Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018 Jun 29;: Authors: Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PD, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD, Clinical Research Alliance of the Crohn’s and Colitis Foundation Abstract BACKGROUND & AIMS: Parenteral methotrexate induces…

Read More
<< Go Back